Document:

restated xponent data license agreement

	

IMS HEALTH INCORPORATED 

Restated Xponent
Data License Agreement 

        AGREEMENT,
dated as of this 26th day of April, 2001, with an effective date of September
1, 2000 (“Effective Date”) by and between IMS Health Incorporated (hereinafter
“IMS”), a Delaware corporation with an address at 200 Nyala Farms, Westport,
Connecticut 06880, and the Interactive Marketing Division of Synavant Inc., (formerly
known as Clark O’Neill) (hereinafter “Licensee”), a Delaware corporation,
with an address at One Broad Avenue, Fairview, New Jersey 07022. This Agreement supercedes
the Xponent Data License Agreement signed on August 31, 2000. 

RECITALS 

        WHEREAS,
IMS is principally engaged in providing information services to the pharmaceutical
industry and, in connection therewith, collects data from pharmacies through various third
parties relating to prescription transactions and prescribers; 

        WHEREAS,
Licensee on behalf of its customers, is principally engaged in providing direct marketing
of pharmaceutical promotion to prescribers in the United States and circulation management
of healthcare professional publications in the United States; and 

        WHEREAS,
IMS desires to license certain data to Licensee in accordance with and subject to the
terms set forth in this Agreement: 

        NOW
THEREFORE, in consideration of the foregoing and of the mutual promises herein contained,
the parties agreement as follows: 

	 	1.  	DEFINITIONS 

	 	          For
purposes of this Agreement, the following terms shall have the meanings specified:  

	 	 	 

	 	a.  	“affiliate” of
Licensee means any Person which now or in the future                controls, is
controlled by or is under common control with Licensee.  

	 	b.  	“Agency” means
an agency engaged by a Manufacturer to develop and/or                implement a
marketing campaign for one or more of such Manufacturer’s                Legended
Drugs.  

	 	c.  	“Association” means
a professional association, comprised of members                in a health care-related
profession, which is, pursuant to the terms of                Paragraph 8(a), identified
by IMS as licensing data to IMS that is incorporated                into certain elements
of the Data  

	 	d.  	“Contract
Year” means each 12-month period commencing on September 1                and ending
on August 31 during the term of this Agreement.  

	 	e.  	“Data” means
certain data provided by IMS from its Xponent®               PlantrakTM and
Xponent® ProfilerTM information services and other                services as
further described on Exhibit 1 hereto.  

	 	f.  	“Desktop
Media” means prescription pads, medical forms and other                similar
promotional materials which are provided to Prescribers at a nominal
               charge or without charge, and which contain advertising relating to one of
more                Legended Drugs.  

	 	g.  	“Healthcare
Company” means (i) a manufacturer of Legended Drugs or                over the
counter (“OTC”) products or any Person licensed by such a
               manufacturer to market and sell Legended Drugs or OTC products
               (“Manufacturer”) or an Agency; provided, however, that neither a
               wholesaler of Legended Drugs, a pharmacy, nor a Person providing mail
service                prescription drug programs shall be deemed a “Manufacturer”;
(ii) a                manufacturer of medical supplies and/or diagnostic equipment, or
any person                licensed by such a manufacturer to market and sell medical
supplies and/or                diagnostic equipment; (iii) a publisher of single or
multi-sponsored journals                which are devoted to medicine, health care or
veterinary subjects                (“Journals”); (iv) a publisher of Desktop
Media, (v) a sponsor of                continuing medical education (“CME”)
seminars, conferences or courses                or a publisher of CME materials or (vi) a
pharmacy benefits management company                or “PBM”.  

	 	h.  	“Legended
Drugs” means drugs, which under Federal or state law require                the
written prescription of a doctor, osteopath or other individual who has the
               authority to prescribe Legended Drugs.  

	 	i.  	“Materials” means
(i) information, including promotional materials and                solicitation
materials sent to a Prescriber, all of which related to one or more
               Legended Drugs or over-the-counter drugs of a Manufacturer or relate to
medical                supplies and/or diagnostic equipment marketed by a Healthcare
Company, (ii)                surveys or questionnaires sent to a Prescriber which either
seek information                related to the prescribing or practice profile of such
Prescriber or the use by                such Precriber of medical supplies or diagnostic
equipment; provided, however,                that the use of such surveys or
questionnaire shall be subject to the terms of                Paragraph 6(c) hereof,
(iii) Journals, (iv) Desktop Media, or (v) information,                including
promotional materials, solicitation materials or course materials,
               relating to CME.  

	 	j.  	“Person” means
any natural person, corporation, business trust, joint                venture,
association, company, firm, partnership, government entity or other
               entity.  

	 	k.  	“Prescriber” means
a doctor, osteopath, dentist or other individual                with an address in the
United States who has the authority to prescribe Legended                Drugs.  

	

2 

	 	2.  	LICENSE
GRANT
 IMS hereby grants to Licensee a non-transferable and non-exclusive license, without
the right to grant sublicenses, to Data for use solely in accordance with the terms of
Paragraph 4 and 5 hereof and subject to the other terms and conditions of this Agreement
and only for the uses as specified in Exhibit 3. The licenses granted herein are not
exclusive, subject to Exhibit 5, and nothing contained herein shall prohibit or restrict
IMS from licensing, selling or otherwise transferring Data or any other information to
any other Person or from using Data or any other information for its own purposes. 

	 	3.  	DATA

 IMS shall provide the Data to Licensee in accordance with the operational procedures set
forth on Exhibit 2 hereto. IMS will use its reasonable efforts to process Data in an
accurate and complete manner. IMS will promptly notify Licensee of any material
inaccuracies in such Data, which become known to IMS in accordance with IMS’s then
applicable internal procedures for data quality assurance. 

	 	 	 

	 	4.  	USE
OF DATA
Subject to the other terms and conditions of this Agreement, the Data licensed
hereunder, shall be used by Licensee solely for the uses and purposes listed on Exhibit 3. 

	 	5. 	CONDITIONS APPLICABLE TO USE OF DATA 

	 	a.  	The
delivery of any Materials, Legended Drug samples or over-the-counter drug
               samples in connection with Paragraph 4 may be made by U.S. Postal Service,
other                common carrier, telegram, telephone, facsimile transmission,
internet, modem or                other means; provided, however, that under no
circumstances (except as noted                below) shall delivery of any of such
Materials or Legended Drug samples be                accomplished by (i) any employee of
a Manufacturer, including but not limited to                any pharmaceutical sales
representative of such Manufacturer, or (ii) any Person                engaged by a
Manufacturer to call on Prescribers on behalf of such Manufacturer                in
connection with the marketing of one or more Legended Drugs, except that in
               the event that the Manufacturer is a licensee of Xponent® prescriber
level                data for the same products, and therapeutic classes during the
applicable time                periods, the prohibition set forth above in this paragraph
5a does not apply,                provided that Licensee has secured advance written
approval of IMS (e.g.                execution of a Third Party Access Agreement).
Notwithstanding the above, in the                event that a Prescriber has requested
that Licensee deliver a Legended Drug                sample, or Materials, as a result of
Licensee’s First Rx or sample                fulfillment programs, and the
Manufacturer of the Legended Drugs or the                Manufacturer of the Legended
Drug that is described in the Materials is not a                Licensee of Xponent® prescriber
level data for the same products and                therapeutic classes, Licensee, for
three (3) programs only for any twelve (12)                month period, will be allowed
to permit a person described in (i) or (ii) above,                to deliver the
Materials and/or Legended Drug samples to the Prescriber;                provided however
that (a) Licensee provides IMS with three (3) days prior                written notice,
and (b) each such program does not exceed supplying five                thousand (5,000)
Prescribers with Legended Drug samples and/or Materials.  

	

 3

	 	b.  	The
use of any list of Prescribers selected by Licensee from the Data pursuant
               to the terms of Paragraph 4 shall be limited to a specific one-time use or
a                single marketing program conducted by Licensee for a Healthcare Company
or any                renewal or repeat of such program by Licensee; provided, however,
that with the                exception of Limited Data, and the retention of Historical
Data as provided                under Paragraph 11(c), and Data, or any information
derived from such Data,                contained in or identified with such list may only
be used in a manner permitted                hereunder for a period not to exceed ninety
(90) days, after which such Data                must be destroyed. In the event any Data
or any information derived therefrom is                copied or incorporated into any
database, data bank or any file or listing                containing any data not
provided pursuant to the terms of this Agreement, such                database, data
bank, file or listing, as the case may be, shall be and remain                subject to
all of the terms and conditions of this Agreement.  

	 	 	 

	 	c.  	Except
as provided under Paragraphs 5(d), 5(e) and 18 hereof, Licensee shall
               retain the Data and any information derived therefrom only within the
internal                confines of Licensee’s own organization. The parties hereto
acknowledge and                agree that the preceding sentence is fundamental to this
Agreement and Licensee                shall not design programs or provide multiple
copies of list to a Healthcare                Company which taken together would result
in either directly or indirectly                avoiding the restriction contained in the
preceding sentence. Licensee shall not                provide any data to any third
party, including but not limited to a Healthcare                Company or any affiliate
of Licensee, except as specifically set forth below:  

     	(1) 	       

           If a Healthcare Company engages a third party to provide lettershop or similar
          services in connection with sending Materials to Prescribers (a
          “Lettershop”), Limited Data may be provided by Licensee to the
          Lettershop; provided, however, Licensee enters into a written agreement with
          such Lettershop in accordance with Paragraph 5(f)(1) of this Agreement. The
          Lettershop shall be required to return Limited Data to Licensee or the
          Healthcare Company, as the case may be, within ten (10) calendar days of the
          earlier of completion or termination of the respective order for services. 

          

     	(2) 	       

           In the event Licensee selects a list of Prescribers from the Data for use in
          connection with providing Materials or Legended Drug samples to certain of such
          Prescribers on behalf of a Manufacturer, Licensee may provide Limited Data to
          such Manufacturer for the sole purpose of permitting such Manufacturer to notify
          its sales representatives of Prescribers within each sales representative’s
          territory who were sent such Materials or Legended Drug samples; provided,
          however, Licensee send a purchase order to such Manufacturer or enters into a
          written agreement with such Manufacturer in accordance with Paragraph 5(f)(2) of
          this Agreement and provided further that Limited Data derived in whole or in
          part from Data is not provided to a Manufacturer any more frequently than once
          in any thirty (30) day period. 

          

	

4 

     	(3) 	       

           In connection with the delivery to a Prescriber of any sample of a
          Manufacturer’s Legended Drugs in response to a solicitation made pursuant
          to Paragraph 4, Licensee may provide Limited Data to such Manufacturer, and such
          Manufacturer shall be permitted to retain Limited Data relating to the
          recipients of such Legended Drug samples solely for purposes of compliance with
          any applicable state and Federal laws, including but not limited to laws
          relating to the distribution of Legended Drug samples, such period of retention
          in each instances to be limited to the longest period of time necessary to
          comply with any such laws or as otherwise reasonably provided by agreement
          between Licensee and its customer. 

	 	 	 

	 	d.  	Licensee
may provide the following types of information derived from the Data to                a
Healthcare Company that is a prospective customer for a specific service of
               Licensee that involves the selecting of lists of Prescribers, derived from
the                Data for the uses permitted by the terms of Paragraph 4 of this
Agreement,                solely for purposes of promoting such service provided such
information does not                identify individual Prescribers and is not summarized
by and/or identified with                any geographic area or unit including but not
limited to zip codes, counties,                state or sales territories, (except that
Licensee may aggregate the Data and                provide a prospective customer such
aggregated information for one state or one                region (e.g. New England),
only) but aggregates Prescribers only in the                following manner:  

     	(1) 	       

           by Prescriber specialty, the total number of Prescribers per specialty
          contained in the Data, and/or 

          

     	(2) 	       

           by prescribing level, in quintiles or deciles. 

	 	 	 

	 	e.  	Licensee
may provide to a Healthcare Company for whom Licensee has provided a
               product or service which uses Data as permitted under Paragraph 4 in
connection                with a single marketing program, the total number of
Prescribers that were sent                Materials or responded to Materials from
Licensee, as the case may be, with                respect to such program.  

	 	 	 

	 	f.  	If
at any time Licensee provides any Limited Data or any information derived
               from such Data to:  

     	(1) 	       

           A Lettershop, Licensee shall enter into a written agreement with such
          Lettershop, which agreement shall, among other things, contain such terms and
          conditions as are necessary or desirable to prohibit such Lettershop from making
          any use of such Limited Data and/or information in a manner which is
          inconsistent with the terms and conditions of this Agreement. Such terms and
          conditions at a minimum, shall include: 

          

	 	(a)  	a
provision stating that the Limited Data is being provided to the Lettershop
          solely for the limited purpose set forth in Paragraph 5(c)(1); 

	

 5

	 	 	 

	 	(b)  	       terms
and conditions which reflect the obligations and restrictions contained           in
Paragraphs 5(a), 5(b), 5(c)(1), 5(g), 5(h), 6, 7 and 8;  

	 	 	 

	 	(c)  	           a
provision stating that the use of Limited Data is limited to a specific
          one-time use or use in connection with a single marketing program, as the case
          may be; and 

	 	 	 

	 	(d)  	           a
provision stating that IMS Health Incorporated is an intended third party
          beneficiary to the agreement between Licensee and such Lettershop. In the event
          a Lettershop fails to comply with such an agreement, Licensee shall promptly
          notify an appropriate representative of such Lettershop in writing of such
          failure, with a copy to IMS, within five business days after Licensee knows or
          reasonably suspects such failure. Licensee shall promptly provide IMS with a
          copy of any correspondence between Licensee and such Lettershop relating to
such           failure. IMS shall have a right to bring an action as an intended third
party           beneficiary to enforce the terms and conditions of the agreement between
          Licensee and such Lettershop to the extent such terms and conditions are
          required by the terms of this Paragraph 5(f). In the event IMS does not have
          rights as an intended third party beneficiary to bring an action as
contemplated           in this Paragraph 5(f), Licensee agrees to be liable for any
breach by such           Lettershop of such agreement.

	 	 	 

	 	(2)  	A
Manufacturer, Licensee shall either send an order form to such Manufacturer           or
enter into a written agreement with such Manufacturer which order form or
          agreement, as the case may be, shall, among other things, contain such terms
and           conditions as are necessary or desirable to prohibit such Manufacturer from
          making any use of such Limited Data and/or information in a manner which is
          inconsistent with the terms and conditions of this Agreement. Such terms and
          conditions, at a minimum, shall include:  

	 	 	 

	 	(a)  	           a
provision stating that the Limited Data is being provided to the Manufacturer
          solely for one or both of the limited purposes set forth in Paragraph 5(c)(2)
          and (3);  

	 	 	 

	 	(b)  	             terms
and conditions which reflect the obligations and restrictions contained           in
Paragraphs 5(a), 5(b), 5(c)(2) and/or 5(c)(3), as the case may be 5(g), 5(h),
          6, 7 and 8;  

	 	 	 

	 	(c)  	a
provision stating that the use of Limited Data is limited to a specific
          one-time use and/or use in connection with a single marketing program; 

	 	 	 

	 	(d)  	           a
provision stating that such Manufacturer is not permitted to store the           Limited
Data in any database or otherwise use the Limited Data to target the           calling
activity of its sales representatives on Prescribers; and  

	

6 

	 	 	 

	 	(e)  	           a
provision stating that IMS Health Incorporated is an intended third party
          beneficiary to the agreement between Licensee and such Manufacturer. 

	 		 

	 		In the
event a Manufacturer fails to comply with such an agreement, Licensee shall promptly
notify an appropriate representative of such Manufacturer in writing of such failure,
with a copy to IMS within five business days after Licensee knows or suspects such
failure. License shall promptly provide IMS with a copy of any correspondence between
Licensee and such Manufacturer relating to such failure. IMS shall have a right to bring
an action as an intended third party beneficiary to enforce the terms and conditions of
the agreement between Licensee and such Manufacturer to the extent such terms and
conditions are required by the terms of this Paragraph 5(f). In the event IMS does not
have rights as an intended third party beneficiary to bring an action as contemplated in
this Paragraph 5(f), Licensee agrees to be liable for any breach by such Manufacturer of
such agreement. 

	 		 

	 		Such agreements
shall specify the intended uses of such Limited Data in sufficient detail so that it may
be determined whether such use is in compliance with the terms and conditions of this
Agreement. Such agreements shall be available to IMS in connection with any inspection,
which IMS may perform pursuant to Paragraph 17 of this Agreement. 

          	 	g. 	
               In connection with any use of Data under no circumstances shall any of such Data
               or any information derived therefrom be disclosed to a Prescriber or to any
               other Person except as expressly provided herein. 

               

          	 	h. 	
               Notwithstanding anything to the contrary contained herein, under no
               circumstances shall any Data or Limited Data be provided by Licensee to any
               Person which has one or more lines of business engaged in the licensing, selling
               or providing of access to data, information or databases in competition with IMS
               or any Subsidiary (“Competing Company”), or any Person controlling,
               controlled by or under common control with a Competing Company, including but
               not limited to the Competing Companies listed on Exhibit 4; provided, however,
               that nothing herein shall preclude Licensee, a Manufacturer or an Agency from
               engaging a Lettershop of the delivery of Materials in accordance with the terms
               of Paragraph 5(a) and in connection therewith, providing Limited Data to such
               Lettershop in accordance with Paragraph 5(c)(1), provided Licensee complies with
               the terms of Paragraph 5(f)(1). 

               

	 	
As
used in this Paragraph, “Limited Data” shall mean Data limited to the following
fields of information: Prescriber name and Prescriber address to which the Material or
Legended Drug sample was sent or to be sent. Limited Data shall also include Association
Data, provided Licensee has an appropriate license with respect to such Data and further
provided the use of such Association Data and if applicable, the disclosure of such
Association Data, is permitted under the terms of such license.

	

7 

	 	 	 

	 	6.  	PROHIBITED
USES OF DATA
IMS does not grant, and Licensee does not receive any title or other interest in the Data or
any information derived therefrom, including but not limited to the Limited Data, except
for those rights granted explicitly in this Agreement; all rights not expressly granted to
Licensee are reserved to IMS. Without limiting the generality of the foregoing, under no
circumstances shall Licensee use, or permit any other Person to use, Data received by
Licensee in connection with this Agreement or any information derived therefrom, including
but not limited to the Limited Data, in any manner which: 

	 	 	 

	 	a.  	is
contrary to the terms of this Agreement or is otherwise not expressly
               permitted by the terms of this Agreement;  

	 	 	 

	 	b.  	will
violate any law or regulation by such use;  

	 	 	 

	 	c.  	will
violate the contractual restrictions of any Association identified by IMS
               pursuant to Paragraph 7(a) governing the use of such Association’s
data                incorporated within the Data in effect at the time of the use of such
Data,                unless an authorized representative of IMS provides Licensee with
written notice                that such Data is no longer subject to the restrictions of
such                Association’s agreement;  

	 	 	 

	 	d.  	results
in any analysis of the Data, or any information derived therefrom, which
               analysis (i) results in the disclosure to one or more Persons of any
information                regarding the mathematical algorithms formulas, processes, or
projection or                statistical methods used by IMS to produce any of the Data,
(ii) is used or made                available for use to promote or aid in the promoting
of any data or information                which is not derived from the Data, or (iii)
seeks to demonstrate that the Data,                or any information derived therefrom,
is inferior to any other data, attempts to                show any deficiency in such
Data or information, or otherwise makes statements                detrimental to IMS
concerning such Data or information;  

	 	 	 

	 	e.  	results
in the selection of Prescribers from which a Manufacturer, an Agency,
               Licensee or any other Person solicits information on practice profiles
and/or                prescribing activity for the purpose of developing a database of
practice and                prescribing profiles on individual Prescribers, except for
the solicitation of                such information for the benefit of (i) a single
Manufacturer or (ii) a single                Healthcare Company that is a manufacturer of
medical supplies and/or diagnostic                equipment or (iii) a publisher of
desktop media. Notwithstanding the above, with                respect to the developing
of practice profile databases of Prescribers by                Licensee, Licensee may
develop a database of practice profile information                derived from the use of
the Data if such practice profile information is (i) not                information that
IMS regularly collects, creates or possesses in the ordinary                course of its
businesses, (ii) the practice profile information is only                indirectly
derived from the Data (i.e. Data is used to solicit practice profile
               information for Prescribers and does not contain anything from the Data
itself                other than Limited Data) and (iii) the practice profile information
does not                reflect attitudes and self-reporting behavior relating to the
prescribing of                Legended Drugs.  

	

8 

	 	 	 

	 	f.  	applies
one or more mathematical algorithms, formulas or processes to any of the
               Data for the purpose of estimating or projecting any new data or
information;  

	 	 	 

	 	g.  	results
in the reverse engineering or disassembling of any of the Data;  

	 	 	 

	 	h.  	enhances,
benchmarks, validates, compares with, authenticates, verifies,
               supplements, or modifies any data, products or services of Licensee or any
other                party except as expressly provided in this Agreement;  

	 	 	 

	 	i.  	facilitates,
authorizes or otherwise expressly or tacitly permits the                incorporation of
the Data, or any information derived therefrom, in any sales                force
automation systems, electronic territory management system, customer
               relationship management system, or any other similar system used by sales
               representatives for call reporting and management of sales information for
their                respective territories, except as expressly provided in Paragraph
5(c)(2);  

	 	 	 

	 	j.  	facilitates,
authorizes or otherwise expressly or tacitly permits the use of any                Data,
or any information derived therefrom, by a Manufacturer for use in
               connection with the compensation or management of such Manufacturer’s
sales                force(s); or  

	 	 	 

	 	k.  	facilitates,
authorizes or otherwise expressly or tacitly permits the use of any                Data,
or any information derived therefrom, by a Manufacturer for targeting of
               Prescribers by the sales representatives of such Manufacturer.  

	 	 	 

	 	7.  	ASSOCIATION
DATA 

	 	 	 

	 	a.  	IMS
may identify to Licensee in writing certain elements of some or all of the
               Data, which incorporates information licensed to IMS by an Association
               (“Association Data”). In addition to the terms and conditions of
this                Agreement, Licensee agrees to treat each element of Association Data
in                accordance with the terms of the respective Association agreement then
in effect                between IMS and such Association. To the extent that any term of
such an                Association agreement then in effect is more restrictive
concerning the use or                disclosure of Association Data than the terms
contained in this Agreement                concerning the use or disclosure of Data, then
the terms of such Association                Agreement shall control, but only with
respect to the use or disclosure, as the                case may be by Licensee of
Association Data.  

	 	 	 

	 	b.  	In
the event IMS identifies Association Data pursuant to Paragraph 7(a) above
               and Licensee fails to maintain the requisite license with the Association
               licensing such data to IMS which would permit Licensee, at a minimum, a
right to                use the Association Data provided hereunder in the manner
contemplated herein,                IMS shall have no further requirement to provide such
Association Data under the                terms of this Agreement until such time as
Licensee obtains such a license.  

	 	 	 

	 	c.  	By
way of example, and not by way of limitation, any element of Data
               identifying:  

	

9 

     	(1) 	       

           the Medical Education number of the Prescriber is derived from the American
          Medical Association’s (“AMA”) Physician Professional Data and
          shall remain subject to the terms and conditions of the applicable AMA agreement
          then in effect between IMS and the AMA. 

          

     	(2) 	       

           the American Osteopathic Association (“AOA”) number of the Prescriber
          is derived from the AOA’s data files and shall remain subject to the terms
          and conditions of the applicable AOA agreement then in effect between IMS and
          the AOA. 

          

	 	8.  	CONFIDENTIALITY

Licensee hereby acknowledges that the Data are proprietary to IMS (collectively “Confidential
Information”), agree to protect the proprietary and confidential nature of such
Confidential Information and in connection therewith, will prohibit any access to or
copying or disclosure of any of the Confidential Information during the terms of this
Agreement and after termination of this Agreement, except (a) that access to and
disclosure of Confidential Information may be provided to those employees of Licensee, in
connection with the uses permitted Licensee as described in Exhibit 3 who require same to
carry out such uses, and (b) as expressly permitted under Paragraphs 5(c), (d) and (e) of
this Agreement. Licensee and any such other persons who receive access to or disclosure
of Confidential Information pursuant to the preceding sentence shall maintain the strict
confidentiality of such Confidential Information in the same manner as Licensee maintains
the confidentiality of its own confidential information, and Licensee will not disclose
such Confidential Information except as expressly provided herein. In the event any of
such other persons fail to comply with the confidentiality obligations contained in this
Paragraph 8, Licensee shall promptly notify an appropriate representative of such person
in writing of such failure, with a copy to IMS within five business days after Licensee
knows or suspects such failure. Licensee shall promptly provide IMS with a copy of any
responses from such person to Licensee’s notification. IMS shall have a right to
bring an action as an intended third party beneficiary to enforce the terms and
conditions of the agreement between Licensee and such person with respect to obligations
of confidentiality. In the event IMS does not have rights as an intended third party
beneficiary to bring an action as contemplated in this Paragraph 8, Licensee agrees to be
liable for any breach by such person of such agreement. Licensee agrees that it will not
ever, either during the term of this Agreement or after its termination, assert that Data
are not, were not or will not be proprietary to IMS and subject to copyright held by IMS
with the exception of elements of Association Data which is proprietary to the respective
Association and subject to copyright held by such Association. 

	

10 

	 	 	 

	 	9.  	REPRESENTATIONS
AND WARRANTIES
 IMS represents and warrants that it has the right and authority to license
the Data to Licensee under this Agreement. EXCEPT AS EXPRESSLY STATED IN THE PRECEDING
SENTENCE OR PARAGRAPH 3, IMS MAKES NO WARRANTY OR REPRESENTATION, EXPRESS OR IMPLIED, AS
TO THE DATA (INCLUDING BUT NOT LIMITED TO ANY WARRANTY OF MERCHANTABILITY OF SUCH DATA OR
ITS FITNESS FOR LICENSEE’S PARTICULAR PURPOSE) AND FURTHER MAKES NO WARRANTY OR
REPRESENTATION, EXPRESS OR IMPLIED AS TO THE ACCURACY OR COMPLETENESS OF THE DATA. 

	 	 	 

	 	10.  	LIMITATION
OF LIABILITY
 IMS’s entire liability and Licensee’s exclusive remedy for IMS’s
failure to abide by the accuracy and completeness requirements of Paragraph 3 shall be
for IMS to endeavor to correct, in accordance with IMS’s then applicable operating
procedures for data quality assurance, any such non-conformance which has been reported
by Licensee to IMS in writing in a timely manner in accordance with Exhibit 2.
Notwithstanding any injunctive relief which Licensee may be entitled to, IMS shall not be
liable for any indirect, consequential, punitive, incidental or special damages to
person, property or business which may be caused by any use, failure to provide or
unavailability of Data or any breach by IMS of its obligations hereunder (even if IMS has
been advised of the possibility of such damages). 

	 	 	 

	 	11. 	TERM/TERMINATION

	 	 	 

	 	a.  	The
term of this Agreement shall be for a three (3) year period commencing on
               the date first written above. Licensee shall have the right to terminate
this                Agreement at the end of each contract year of this Agreement provided
that                Licensee give IMS one hundred, eighty (180) days written notice prior
to the end                of the then existing contract year, of its intention to
terminate.                Notwithstanding the foregoing, IMS shall have the right to
terminate this                Agreement on thirty (30) days advance written notice to
Licensee:  

     	(1) 	       

           if Licensee becomes insolvent, voluntarily files a petition under any federal
          or state bankruptcy law for itself, has an involuntary petition filed under any
          federal or state bankruptcy law against it which is not removed within thirty
          (30) days of filing, ceases operations for at least thirty (30) days with the
          intent of winding up Licensee’s business, or otherwise publicly announces
          the termination of its operations and/or substantially all the products relating
          to the licenses granted herein; 

          

     	(2) 	       

           upon the sale of Licensee, whether by merger, consolidation, the sale of its
          stock or by the sale of all or substantially all of its assets to a Competing
          Company or any Person controlling, controlled by or under common control with a
          Competing Company; or 

          

     	(3) 	       

           if Licensee or any affiliate of Licensee develops or comes into possession of
          data, which is substantially similar to the Data or Licensee, or any affiliate
          of Licensee acquires the right, by license, purchase or otherwise, to data which
          is substantially similar to the Data. 

          

	

11 

	 	
As
used in Paragraph 11(a)(3), data which is “substantially similar to the Data”
shall include but not be limited to any data or information (a) consisting of or derived
from a number of prescription transactions in any calendar month which number is greater
than or equal to one-twentieth (1/20th) of the number of prescription
transactions as estimated by IMS’s National Prescription Audit for such calendar
month, or (b) which Licensee or any affiliate of Licensee claims is the functional or
statistical equivalent of data that consists of or is derived from a number of
prescription transactions in any calendar month which number is greater than or equal to
one-twentieth of the number of prescription transactions as estimated by IMS’s
National Prescription Audit for such calendar month. However, data shall not be considered
“substantially similar to the Data” for any data received from a pharmaceutical
Manufacturer for use by Licensee solely to provide services to such Manufacturer.

	 	 	 

	 	b.  	In
the event of the termination of this Agreement:  

     	(1) 	       

           Licensee shall deliver all Data, and any information derived therefrom, (except
          for Licensee’s client’s proprietary information that has been supplied
          to Licensee by client) in its possession or control to IMS within ten (10) days
          of such termination except as otherwise expressly provided in Paragraph 11(c). 

          

     	(2) 	       

           for any period during which Data, or any information derived therefrom, remains
          in the possession or control of Licensee after termination of this Agreement,
          such Data and information shall remain subject to the restrictions contained in
          this Agreement, including but not limited to those restrictions contained in
          Paragraphs 4, 5, 6, 7, and 8. 

          

	 	
This
provision shall not be construed to limit survival of any other provision, which also
survives the termination of this Agreement by the express or implied terms of such
provision.

	

12 

	 	 	 

	 	c.  	In
connection with the selection of a list of Prescribers for a use permitted
               pursuant to Paragraph 4, Licensee is authorized to maintain for a period
of                three years (or longer to the extent required by law) from the date
following                the termination of this Agreement historical files containing
the following data                elements from Data: physician name, physician address
used in connection with a                delivery made in accordance with the terms of
this Agreement, Prescriber                identification number and Prescriber specialty
(collectively “Historical                Data”). Such Historical Data may be
maintained for such three year period                only for the following purposes: (i)
servicing a possible Legended Drug product                recall pursuant to applicable
regulations promulgated by a government agency                whereby notices are
delivered to Prescribers chosen from a list produced by                Licensee under the
terms of this Agreement to whom samples of such Legended                Drugs were sent,
(ii) recreating a delivery made on behalf of a Healthcare                Company
pursuant to the terms of this Agreement in which an error was made                either
by Licensee and/or the Healthcare Company, as the case may be, which                error
is the sole reason for recreating such delivery, or (iii) responding to an
               audit or written request of a governmental agency for information on the
               recipients of a Legended Drug sample delivered in the fulfillment of a
request                by a Prescriber in response to a solicitation made pursuant to
Paragraphs 4(a),                4(b) or 4(d). Within thirty (30) days following the end
of such period, the                Historical Data for such deliveries will be deleted
from Licensee’s                possession and control.  

	 	 	 

	 	12.  	DEFAULT 

	 	 	 

	 	a.  	A
“Default” shall exist hereunder by Licensee if Licensee fails in any
               material respect to be in compliance with the terms of Paragraphs 2, 4, 5,
6, 7                or 8 (an “Event of Default”) and such failure, if curable,
is not                cured within ten (10) calendar days following notice of such
failure from IMS.  

	 	 	 

	 	b.  	If
IMS alleges an Event of Default by Licensee, and Licensee in good faith
               disputes the occurrence of such Event of Default, IMS agrees to continue
to                provide Data hereunder until such dispute is resolved by the parties or
by a                determination through arbitration as provided in Paragraph 16,
without                prejudice to any remedies available to IMS.  

	 	 	 

	 	13.  	CERTAIN
REMEDIES 

	 	 	 

	 	a.  	If
the sale of any product or the rendering of any service or the license of any
               Data gives rise to an Event of Default pursuant to Paragraph 2 or 4 of
this                Agreement, then IMS shall receive from Licensee an amount equal to
the aggregate                of the gross revenues recognized from the same of such
product or the fees                charged in connection with the rendering of such
service or the licensing of                such Data.  

	

13 

	 	 	 

	 	b.  	Two
or more Events of Defaults hereunder, whether or not cured, shall entitle
               IMS, in its sole discretion, to immediately terminate this Agreement upon
               written notice to Licensee; provide however, that each such Event of
Default is                acknowledged in writing by Licensee and/or is finally
determined by arbitration                pursuant to Paragraph 16 of this Agreement.  

	 	 	 

	 	c.  	Noting
herein shall be construed as limiting IMS’s rights and remedies, in
               the event of a breach of this Agreement by Licensee, whether or not such
breach                is cured. The rights and remedies set forth in Paragraphs 11 and 13
of this                Agreement are in addition to any other rights or remedies which
otherwise may be                available, in law or in equity.  

	 	 	 

	 	14.  	FORCE
MAJEURE
Licensee agrees that IMS shall not be deemed to have breached this Agreement  or
to be liable for any damages caused by failure to perform or by delay in rendering
performance hereunder arising out of any occurrence or contingency beyond its reasonable
control, including but not limited to (a) flood, earthquake, fire, war, strikes, labor
unrest, riot, civil commotion, power or communication line failure, computer equipment
failure or operational failure, (b) failure of independent contractors under agreement
with IMS to perform or a delay in such performance, failures, delays or restrictions of
sources from which information or data is obtained, or failure of performance by
Licensee, or (c) prohibition(s) or restrictions(s) imposed by applicable regulatory
authority, the judgment, ruling or order of a court or agency of competent jurisdiction,
or the enactment of or change in any law or regulation. 

	 	 	 

	 	15.  	ADDITIONAL
AGREEMENTS 

	 	 	 

	 	a.  	IMS
and Licensee each agree to keep the terms of this Agreement in confidence
               and not disclose them to any other Person, except for those terms of the
               Agreement required to be disclosed (i) pursuant to federal or state laws
or                regulations including securities laws and their related disclosure
requirements,                (ii) pursuant to judicial or arbitration orders and
proceedings, (iii) as may be                required to perform their obligations under
this Agreement, or (iv) to each of                IMS’s and Licensee’s legal
and financial representatives who need to                know such terms solely for the
purpose of providing legal and financial advice                to each such party,
respectively. This provision shall not prohibit either party                from
disclosing the existence of this Agreement or that IMS is a data source.  

	 	 	 

	 	b.  	Upon
the request of IMS, the President of Licensee (or in the event the
               President of Licensee is not responsible for the day-to-day business of
               Licensee, then the General Manager of Licensee or such other person who
has                overall responsibility for the day-to-day business of Licensee) shall
provide                IMS with a written statement certifying that, after due inquiry,
Licensee has                complied in all materials respects with Licensee’s
obligations under the                provisions of Paragraphs 2, 4, 5, 6, 7 and 8 of this
Agreement for the past                Contract Year, except as noted therein.  

	

14 

	 	 	 

	 	c.  	Under
no circumstances shall this Agreement be construed as placing any
               affirmative obligation on IMS, express or implied, to collect or continue
to                collect any data or information from any third party, including but not
limited                to pharmacy data from which the Data is derived (“Source Data”).
In                the event IMS determines, in its sole judgment and discretion, to cease
               collecting any Source Data which will result in a substantial reduction in
the                amount of, or the cessation in, the Data delivered hereunder, IMS will
provide                written notice of such at least ninety (90) days prior to the date
on which such                Source Data collection will cease, specifying the date or
dates at which IMS                will cease collecting such Source Data and the
approximate number of                prescriptions that will not be included in the Data
in the ensuing twelve (12)                months as a result (the “IMS Notice”).
In such event, IMS shall incur                no liability to Licensee in connection
therewith and, in the event IMS ceases to                collect all of such Source Data
then this Agreement shall automatically                terminate and be of no further
force and effect immediately upon the last                delivery of Data to Licensee. A
“substantial reduction” means a                reduction in the aggregate
amount of prescriptions comprising the Source Data                for use in connection
with the delivery of Data hereunder in excess of                twenty-five percent (25%)
when compared with the aggregate amount of                prescriptions comprising the
Source Data available to IMS for use in connection                with the delivery of
Data for the same calendar quarter period in the                immediately prior year.  

	 	 	 

	 	d.  	IMS
and Licensee acknowledge that a data supplier to IMS may request that some
               or all of its data be restricted in such a manner as to prevent IMS from
               providing such data, or information derived therefrom to Licensee (“Data
               Supplier Request”). In the event of a Data Supplier Request, IMS may,
at                its sole option enter into an agreement or arrangement or continue an
agreement                or arrangement, as the case may be, which accommodates such
Request; provided,                however, IMS prior to the acceptance of such an
agreement or arrangement, uses                reasonable efforts to persuade such data
supplier to provide its data without                such restriction. For purposes of
this Paragraph 15(d), IMS shall be deemed to                have used “reasonable
efforts” if IMS, in connection with its                negotiations with such data
supplier, makes a bona fide attempt to persuade such                data supplier to
provide its data to IMS without such restriction; provided,                however, under
no circumstances shall IMS have any obligation to increase the                amounts
paid, or to be paid, to such data supplier in exchange for the                elimination
of such restriction.  

	

15 

	 	 	 

	 	e.  	IMS
agrees that, upon the request of Licensee, IMS shall negotiate in good faith
               with Licensee for a period of not more than 30 days with respect to the
               acquisition by Licensee of IMS’s Xponent® information services in
               certain European countries. In the event that the parties have not entered
into                a definitive agreement with respect to such acquisition at the end of
such                30-day period, IMS shall have no further obligations pursuant to this
Section                15(c). The parties acknowledge and agree that nothing in this
Section 15(c)                shall create a binding obligation on IMS or Licensee to
consummate such an                acquisition or shall constitute any expression of the
parties’ intent or                agreement with respect to the terms of any such
acquisition; any such obligation                and such terms will be created and
expressed only by a definitive agreement or                agreements, if any, negotiated
and entered into by the parties.  

	 	 	 

	 	16.  	ARBITRATION 

	 	 	 

	 	a.  	Each
party shall designate a project manager to coordinate such party’s
               activities under this Agreement. Such project managers shall also, when
               necessary, confer in order to resolve problems or disputes that may arise
in                connection with each party’s performance hereunder. If the project
managers                cannot resolve such problems or disputes, such problems or
disputes shall be                referred to each party’s respective senior
management including, if                necessary, its President for discussion and
resolution.  

	 	 	 

	 	b.  	Subject
to Paragraph 16(d) any controversy or claim arising out of or relating                to
this Agreement, and which cannot be resolved in accordance with the procedure
               set forth in the preceding paragraph, shall be submitted to arbitration
before a                panel of three (3) arbitrators. The arbitrators shall be selected
and the                arbitration conducted in accordance with the Commercial Rules of
the American                Arbitration Association. An award shall be conclusive and
binding if concurred                in by two (2) of the arbitrators, and judgment upon
the award rendered by the                arbitrators may be entered in any court having
jurisdiction thereof. The                arbitrators shall be required to deliver a
written decision setting forth their                findings of fact and basis for their
award. The arbitrator’s award shall                provide for the payment of the
arbitrators’ expenses and fees, together                with other expenses incurred
in the conduct of the arbitration proceeding other                than legal fees and
expenses. However, the arbitrators shall award the                prevailing party
reasonable attorneys’ fees and other expenses incurred in                the
arbitration proceeding in the event that the arbitrators determine that
               either party acted in bad faith in connection with either asserting a
claim or a                defense in the arbitration proceeding itself.  

	

16 

	 	 	 

	 	c.  	The
parties hereby agree to submit to the exclusive personal jurisdiction and
               venue of the United States District Court for the Eastern District of
               Pennsylvania for purposes of enforcing the agreement to arbitrate,
providing                provisional relief pending the award, and entering judgment on
the award. If for                any reason the aforesaid court does not have subject
matter jurisdiction the                parties alternatively agree to submit to the
exclusive personal jurisdiction and                venue of the applicable court of the
Commonwealth of Pennsylvania, County of                Montgomery, for the foregoing
purposes. Nothing contained in this paragraph                shall preclude the
arbitrators from granting, where appropriate, injunctive or                other
provisional relief pending a final award.  

	 	 	 

	 	d.  	Notwithstanding,
the provisions of Paragraphs 16(b) and (c), any party hereto                may pursue
any provisional remedy (including but not limited to preliminary
               injunctive relief) to enforce its rights hereunder in the courts
designated in                Paragraph 16(c). The parties shall have the right to obtain
such provisional                injunctive relief from a court of law designated in
Paragraph 16(c) pending the                determination and award in the arbitration
proceeding. The parties may seek                injunctive relief either restraining
certain conduct or mandating certain                conduct. This Paragraph 16(d) shall
not be deemed to limit the power of the                arbitrators to grant any remedy or
relief the arbitrators deem just or                reasonable within the scope of this
Agreement.  

	 	 	 

	 	e.  	The
parties agree that, immediately upon the designation of the arbitrators they
               will request the arbitrators that they set an expedited schedule for the
conduct                of the arbitration proceeding such that the proceeding is
concluded within six                months of the date of the filing of a demand for
arbitration and that an award                shall be rendered within thirty (30) days of
the conclusion of the proceeding.  

	 	 	 

	 	17.  	INSPECTION
RIGHTS/COOPERATION

	 	 	 

	 	a.  	IMS
shall have the right to make an inspection of the business, books and
               records of Licensee upon five (5) days notice to Licensee for the purpose
of                verifying Licensee’s compliance with its obligations pursuant to
Paragraphs                2, 4, 5, 6, 7 and 8 of this Agreement. Licensee shall maintain
business records,                books, account information, computer logs and related
materials sufficient to                permit IMS to verify that Licensee is in
compliance with its obligations under                the above-referenced Paragraphs.  

	 	 	 

	 	b.  	Any
such inspection of Licensee’s books and records, shall be performed by
               IMS’s representatives and/or its outside auditors. The costs of such
an                inspection shall normally be at IMS’s expense. However, Licensee
shall bear                the cost of an inspection if such inspection reveals an Event
of Default or any                other material breach of the terms of this Agreement.  

	

 17

	 	 	 

	 	18.  	MISCELLANEOUS 

	 	 	 

	 	a.  	The
parties hereto are independent contractors engaged in the operation of their
               own respective businesses. Neither party is, or is to be considered as,
the                agent or employee of the other for any purpose whatsoever. Neither
party has the                authority to enter into contracts or assume any obligations
for the other party                or make any warranties or representations on behalf of
the other party. Nothing                in this Agreement shall be construed to establish
a relationship of co-partners                or joint ventures between the parties.  

	 	 	 

	 	b.  	This
Agreement constitutes the entire understanding between the parties and
               supersedes all proposals, commitments, writings, negotiations and
               understandings, oral and written and all other communications between the
               parties relating to the subject matter of this Agreement. This Agreement
               supercedes the Xponent Data License Agreement signed August 31, 2000 in
its                entirety. In the event there is a conflict between the terms of this
Agreement                and the terms of the Distribution Agreement dated August 31,
2000, the terms of                the Distribution Agreement shall prevail.  

	 	 	 

	 	c.  	IMS
may assign all or any portion of this Agreement to an entity which is then
               an affiliated company and any such affiliated company may assign all or
any                portion of this Agreement to an entity which is then an affiliated
company;                provided, however, that any such assignment shall not relieve IMS
of its                obligations under this Agreement if the assignee fails to perform.
This                Agreement may not be assigned from Licensee to any other Person,
whether by                assignment by Licensee, by operation of law or otherwise
without the prior                written consent of IMS, which consent shall not be
unreasonably withheld. The                sale or transfer of a majority of the
outstanding shares of Licensee, or the                merger or consolidation of Licensee
with any other Person, shall be deemed an                attempt by Licensee to assign
its interests in this Agreement which shall first                require the prior
written consent of IMS. Any assignment not expressly permitted                under this
Paragraph 18(c) or which has not received the written consent of the                other
party if required herein shall be void.  

	 	 	 

	 	d.  	Should
any part, term or condition hereof be declared illegal or unenforceable                or
in conflict with any other law, the validity of the remaining portion or
               provisions of this Agreement shall not be affected thereby, and the
illegal or                offensive portions of this Agreement shall be and hereby are
redrafted to                conform with applicable law in a manner which is consistent
with the original                spirit and intent embodied in the original executed copy
of this Agreement,                while leaving the remaining portions of this Agreement
intact.  

	 	 	 

	 	e.  	The
waiver by either party of a breach or violation hereof or remedy provided
               herein shall not operate as or be construed to be a waiver of any
subsequent                breach or violation hereof.  

	 	 	 

	 	f.  	This
Agreement shall be governed by and construed in accordance with the laws of
               the Commonwealth of Pennsylvania without giving effect to principles of
               conflicts of law.  

	

18 

	 	 	 

	 	g.  	Nothing
in this Agreement is intended to benefit and shall not be deemed to
               benefit any person who is not a party hereto or to create any third party
               beneficiary rights.  

	 	 	 

	 	h.  	All
notices pertaining to this Agreement or the performance of either party
               hereunder shall be sufficient if in writing and sent by Federal Express or
other                similar overnight courier service with receipted delivery addressed
to the other                party at the address shown below or to such other address as
a party hereto                shall supply to the other in writing:  

	 	
 

	 	
If to IMS: 

	 	

	 	
IMS Health Incorporated 
660 W. Germantown Pike

                                    Plymouth Meeting, PA  19462

                                    Attention: President

	 	
 

	 	
With a copy to: 

	 	

	 	
IMS Health Incorporated
660 W. Germantown Pike

                                    Plymouth Meeting, PA  19462

                                    Attention: President

	 	
 

	 	
If to Licensee: 

	 	

	 	
Synavant, Inc.
      Interactive Marketing Division

                                    One Broad Avenue

                                    Fairview, NJ  07022

                                    Attention: President

	 	
 

	 	
With
a copy to:  

	 	
Synavant, Inc.
3445 Peachtree Road, N.E.
  Suite 1400
Atlanta, GA  30326

 Attention: President

        Such
notice shall be effective upon receipt by the other party. 

	 	 	 

	 	i.  	Neither
party may under any circumstances utilize the name, trademarks, or
               tradenames of the other, or any names, trademarks, or tradenames so
similar as                likely to cause confusion, without the prior written notice to,
and express                written approval of, the other. Notwithstanding the preceding
sentence:  

     	(1) 	       

           Licensee’s advertising and other promotional materials for products or
          services which use any of the Data shall identify IMS as originator of such
          Data, a copy of which material will be promptly provided to IMS on or before the
          first release of any such material; 

          

	

19 

     	(2) 	       

           Licensee is hereby granted a non-transferable and non-exclusive license,
          without the right to grant sublicenses, to use the trademark Xponent in
          connection with the advertising and promotion of the Data, as such term is
          defined in Exhibit 1, and Licensee agrees to use such trademark in connection
          with its advertising and promotion of any products or services which use Data in
          accordance with the following: 

	 	 	

	 	(a)  	whenever
Licensee uses the Xponent trademark in advertising or in any other           manner in
connection with the Projected Data or any product or services of           Licensee,
which use the Projected Data. Licensee shall clearly indicate           IMS’s
ownership of the trademark; 

	 	 	

	 	(b)  	samples
of all literature, stationery, packages, labels and advertising           prepared by or
for Licensee and intended to be used by Licensee in connection           with the use of
the Xponent trademark shall be promptly provided to IMS by           Licensee on or
before the release of such materials; 

	 	 	

	 	(c)  	when
using the Xponent trademark, Licensee agrees to comply with all laws           pertaining
to trademarks in force at any time in the United States, including           but not
limited to, compliance with marking requirements. 

	 	 	

	 	(d)  	Licensee
agrees to comply with any written usage guidelines provided by IMS for           use of
the Xponent trademark; 

	 	 	

	 	(e)  	Licensee
acknowledges (i) IMS’s exclusive right, title and interest in and           to the
Xponent trademark and will not at any time do or cause to be done any act           or
thing contesting or in any way impairing or tending to impair any part of           such
right, title and interest, and (ii) use by Licensee of the Xponent           trademark
shall not create in Licensee’s favor any right, title or interest           in or to
the XponentTM trademark, but that all uses of the Xponent trademark           by the
Licensee shall inure to the benefit of IMS 

     	(3) 	       

           IMS shall have a right to identify to any Persons (i) that Licensee is a
          licensee of Data from IMS and (ii) those products and services which Licensee
          may use the Data under the terms of this Agreement. 

	 	 	 

	 	j.  	Paragraph
headings herein are for convenience only and do not control or affect                the
meaning or interpretation of any terms or provisions of this Agreement  

	

20 

        IN
WITNESS WHEREOF, the parties have executed this Agreement on the date first written above 

				
	               IMS Health Incorporated:	Synavant Inc.	 	 
	
               By:  BARRY BROUGHTON	
By:  CRAIG KUSSMAN		
	
               Name:  Barry Broughton	
Name:  Craig Kussman		
	
               Title:  Vice President	
Title:  Executive Vice President		
	
               Date:  4/26/01	
Date:  April 26, 2001		

	

21 

	

 

EXHIBIT 1 

FEES & DATA
DESCRIPTION 

 

FEES.                     The
annual fee for the services described in this Agreement for each Contract           Year
shall be one million, two hundred thousand dollars ($1,200,000). IMS shall
          invoice one quarter of the annual fee on a quarterly basis in advance (i.e. IMS
          shall invoice three hundred thousand dollars ($300,000) on or about September
          1st, December 1st, March 1st, and June
          1st of each Contract Year). Licensee shall pay the amount of each
          invoice from IMS within thirty (30) days from receipt of invoice by Licensee.
In           no event shall Licensee deduct or set-off any amount(s) against any
amount(s)           owed to IMS under this Agreement without IMS’ prior written
consent. If           Licensee fails to timely pay any amount in accordance with the
terms of this           Agreement Licensee shall pay in addition to the invoice amount,
interest at the           rate of eighteen percent (18%) per annum on the unpaid balance
beginning           thirty-five (35) days from the date of the invoice until such amounts
are paid.           In addition to any fees which Licensee agrees to pay Licensee shall
have the           exclusive responsibility for and agrees to pay all applicable
governmental           sales, use, added value, ad valorem or other similar taxes,
duties, fees, levies           or other governmental charges now in force or enacted in
the future, except for           taxes based on IMS’s income.  

	 	
 

	 	DATA– Data
shall consist of the following: 

	 	 	 

	 	1.  	Xponent
Profiler (decided Xponent Data)  

	 	 	 

	 	A.  	Data
Elements:  

	 	 	 

	 	                                    o  	Prescriber
ID 

	 	 	 

	 	                                    o  	ME
number and IMS ID number 

	 	 	 

	 	o  	Prescriber
Name  

	 	 	 

	 	o  	Prescriber
Address  

	 	 	 

	 	                                    o  	Prescriber
Specialty 

	 	 	 

	 	                                    o  	Product
Code (or aggregate product codes) 

	 	 	 

	 	                                    o  	Therapeutic
class code 

	 	 	 

	 	                                    o  	Decile
range by therapeutic class 

	 	 	 

	 	                                    o  	Decile
range by product 

	 	 	 

	 	Ancillary  	Data: 

	 	 	 

	 	DRM  	45
for every report  

	 	
A
file identifying all the product changes from the previous deliverable.
A spreadsheet
containing the record count for each tape.

	 	

	

22 

	 	 	 

	 	B.	Frequency
of Delivery: Quarterly  

	 	 	 

	 	C.  	Data
to be Reported in Each Deliverable: Ninety (90) therapeutic classes (same
as received as of June, 2000) with the right to substitute up to ten (10)
          classes per calendar quarter with a minimum of thirty (30) days prior written
          notice given to IMS (but subject to production schedules). Rolling
          twelve(12)months on calendar quarters within current production.  

	 	 	 

	 	D.  	Format: FTP
or Magnetic Tape  

	 	 	 

	 	2.  	Xponent
Plantrak  

	 	 	 

	 	A.  	Data
Elements:  

	 	 	 

	 	o  	IMS
Plan Number  

	 	 	 

	 	o  	Product
Code  

	 	 	 

	 	o  	TRX
Prescription Volume and NRX Prescription Volume (an estimate of total count by Product
Code for each Plan, of the number of prescriptions written from which products have been
dispensed from Pharmacies). 

	 	 	 

	 	o  	TRX
Unit Volume (an estimate of total units (e.g. number of tablets) by product code for each
Plan, from which Products have been dispensed from pharmacies). 

	 	 	 

	 	 o  	Ancillary
Plan Affiliation (Prescriber to Plan linkages) 

	 	 	 

	 	  o  	IMS
Plan Roster File 

	 	 	 

	 	o  	Plan
Name Key  

	 	 	 

	 	   o  	Plan
name and address 

	 	 	 

	 	B. 	Frequency
of Delivery: Once per contract year, upon request  

	 	 	 

	 	C. 	Data
to be Reported in Each Deliverable: Thirty-seven (37) therapeutic           classes
(same as received as of June, 2000 with the right to substitute up to           five (5)
classes per year with a minimum of thirty (30) days prior written           notice to IMS
(but subject to production schedules)  

	 	 	 

	 	D. 	Format: FTP
or Magnetic Tape  

	 	 	 

	 	3. 	Unprojected
Data File (to the extent IMS continues to offer this file to
               customers)for use solely in connection with Licensee’s First Rx
Product as                such product exists on June 1, 2000  

	 	 	 

	 	A.  	Data
Elements:  

	 	 	 

	 	                                    o  	IMS
Prescriber ID Number 

	 	 	 

	 	 o  	ME
number 

	 	 	 

	 	 o  	Product
NDC 

	 	 	 

	 	o  	Week
End Date  

	 	 	 

	 	o  	Date
Dispensed  

	 	 	 

	 	    o  	TRX 

	 	 	 

	 	                                    o  	NRX 

	 	 	 

	 	B.  	Frequency
of Delivery:    Weekly 

	 	 	 

	 	C.	Data
to be Reported in Each Deliverable:   For each product requested, but  for no
more than twenty-four (24) First Rx Product projects per contact year.
          Specifications to be mutually agreed upon for each project.  

	

23 

	 	 	 

	 	D.  	Format:
  FTP or Magnetic Tape  

	 	 	 

	 	E.  	CMF
number for those products involved in the First Rx product. These requests           will
be fulfilled by the Analyst on an ad hoc basis but not more than twelve           (12)
times per calendar year.  

	 	 	 

	 	4.  	IMS
Bridge File  

	 	 	 

	 	A. 	Data
Elements:  

	 	 	 

	 	                                    o  	IMS
ID Number 

	 	 	 

	 	                                    o  	*ME
Number (or other Source ID and Source #3) 

	 	 	 

	 	B. 	Frequency
Delivery:   Quarterly, upon request

	 	 	 

	 	C. 	Data
to be Reported in Each Deliverable:   To be mutually agreed upon.  

	 	 	 

	 	D. 	Format:   FTP
or Magnetic Tape or CD Rom  

	 	 	 

	 	5. 	Analyst – In
order to facilitate Licensee’s receipt of Data and                other Xponent
data, IMS shall make available, for a maximum of twenty (20) hours                per
week, data analyst(s) to: (a) process Licensee’s requests for Data, and
               (b) process Licensee’s requests for other Xponent data for one or
more of                the uses described in Exhibit 3 (other than for use with First Rx)
as more fully                described in an IMS HEALTH Third Party Access Agreement
between IMS and                Licensee.  

	 	
 

	 	
PRODUCT
 For purposes of calculating the number of Products hereunder, a Product shall be
counted for each Product Code reported with one or more Data Value fields, whether the
reporting of such information is by: 

	 	 	 

	 	(1) 	    prescription
volume for a Legended Drug, regardless of form or strength,  

	 	 	 

	 	(2) 	   prescription
volume for a Legended Drug by form, regardless of strength, or  

	 	 	 

	 	(3)  	    prescription
volume for a Legended Drug by form and by strength.  

	 	
For example, and not intended as a limitation, the separate reporting of Drug X in liquid
form at 500mg and 1,000mg strengths and in tablet form at 500mg and 1,000mg strengths
shall constitute four Products. 

	 	
 

	 	
NOTE:   IMS may, in its sole discretion, provide Prescriber Name, Prescriber Address,
Professional Association Number (AMA or AOA only) and Prescriber Specialty linked to the
Prescriber ID on a quarterly basis in a separate file from the Data (“Prescriber File”). 

	 	 	 

	 	*  	For
purposes of this Agreement, the elements of Data identified with an asterisk (*) for (i)
any Data having an ME Number in the Prescriber ID field or otherwise bridged to an ME
Number in the Prescriber File shall be deemed derived from AMA-PPD, and (ii) any Data
having an AOA Number in the Prescriber ID field or otherwise bridged to an AOA Number in
the Prescriber File shall be deemed derived from AOA data. 

	

24

	

 

EXHIBIT 2 

OPERATIONAL
PROCEDURES FOR DATA 

     	 	A. 	
          INITIAL OBLIGATIONS. Within sixty (60) days of the Effective Date of this
          Agreement each party shall designate a Project Manager. The Project Manager of
          both parties shall meet to discuss the implementation of the Data delivery and
          any related issues. 

          

     	 	B. 	
          DATA DELIVERY. Data Delivery shall be in accordance with frequency level
          and format as indicated in Exhibit 1 any amendments thereto. Licensee shall pay
          all shipping and other costs incurred with the delivery of IMS Data. 

          

     	 	C. 	
          CHANGES TO DATA 

          

          	 	1. 	
               Changes to Products. In the event that Licensee seeks to change or add
               products. Licensee shall notify IMS and Licensee shall be charged the price then
               in effect for such change. 

	 	 	 

	 	2. 	       Changes
to Data Elements.  

	 	(a)  	Licensee
Initiated Changes. In the event that Licensee seeks to change           any of the
data elements, Licensee shall notify IMS in writing through its           Project Manager
of the requested change and the parties shall mutually agree to           a fee increase.
IMS in its sole discretion may decline to agree to the change. 

	 	 	 

	 	(b)  	IMS
Initiated Changes. IMS reserves the right to discontinue any product or
service  

          	 	3. 	
               Changes to Reporting Frequency. In the event that Licensee seeks to
               change the reporting frequency, Licensee shall notify IMS in writing through its
               Project Manager of the requested change and the parties shall mutually agree to
               a fee increase. IMS in its sole discretion may decline to agree to the change 

               

     	 	D. 	
          NOTICE OF CHANGES TO DELIVERABLES. Licensee shall send notice to the
          Project Manager of any changes to Data as set forth in section C above. 

          

     	 	E. 	
          PLACE AND METHOD OF DELIVERY. The place of delivery shall be: Synavant,
          One Broad Ave, Fairview, New Jersey 07022. The method shall be via Federal
          Express other overnight mail courier, hand-delivery or other method reasonable
          calculated to reach Licensee promptly. 

          

     	 	F. 	
          LOST OR DAMAGED DATA. Licensee must notify IMS if any Data is lost or
          damaged within ten (10) days from date of delivery. IMS will endeavor to conform
          the Data to the applicable IMS published specifications prevailing at the time
          of shipment, and will provide the replacement Data to Licensee within thirty
          (30) days of notice. 

          

     	 	G. 	
          INSPECTION OF DATA. Licensee shall inspect the Data within ten (10) days
          of receipt. IMS Data shall be deemed to be proper and correct, unless proper
          notice is given to IMS within ten (10) days of receipt of the Data. 

	

25 

	

 

EXHIBIT 3 

DATA USES 

	 	
 

	 	
THE
FOLLOWING USES ARE THE ONLY PERMITTED USES OF THE DATA:  

     	 	A. 	
          The Licensee may use the Data to select, on behalf of a Healthcare Company, a
          list of Prescribers for the purpose of sending Materials, developed by or on
          behalf of such Healthcare Company, to certain of such Prescribers; B. The
          Licensee may use the Data in connection with Licensee’s Single Source
          Sampling product (as that product is defined as of August 31, 2000), to select,
          on behalf of one or more Manufacturers or Healthcare Company, a list of
          Prescribers, which list Licensee may use solely for the purpose of sending its
          order form to certain of such Prescribers soliciting a request from each of such
          Prescribers for one or more Legended Drugs of each of such Manufacturers (a
          “Form”), which form is substantially similar to the form attached
          hereto as Attachment 1; 

          

     	 	B. 	
          The Licensee may use the Data to select on behalf of a publisher of Journals or
          a publisher of Desktop Media, a list of Prescribers for the purpose of
          determining advertisements to appear in a Journal or in a Desktop Media or who
          should receive such Journals; 

          

     	 	C. 	
          The Licensee may use the Data to select on behalf of a Manufacturer or
          Healthcare Company, a list of Prescribers for the purpose of sending Legended
          Drug or OTC products samples of such Manufacturer to certain of such
          Prescribers. 

          

     	 	D. 	
          Licensee may use the Data to report the overall impact and effectiveness of
          Licensee’s products and services provided to its third party customers,
          provided that only topline aggregated Data is provided to the third party. 

          

     	 	E. 	
          Licensee may use the Unprojected Data File for its First RX product (as that
          product is defined as of August 1, 2000) for program targeting for Licensee
          intervention only. 

          

     	 	F. 	
          The Licensee may use information derived from the Data in its proposals to
          customers, provided that only small amounts of topline aggregated information be
          used in such proposals. 

          

	

26 

	

 

EXHIBIT 4 

LIST OF COMPETING
COMPANIES 

	Name	Name
	Abbott Associates, Inc.	Medstart
	AC Neilsen Corporation	McKesson Corporation
	Amaxis	Merck-Medco Managed Care Inc.
	American Healthcare Systems	Migliara/Kaplan Associates (M/K)
	Andersen Consulting (*)	N.A.D.C.
	Archi-Tech Systems, Inc.	National Data Corporation (NDC)
	Beghou Consulting	NFO
	Bergen Brunswig Drug Company	Nomadic Systems, Inc.
	Cardinal Health, Inc.	PCS Health Systems, Inc.
	Common Health Direct	PharmFlex, Inc.
	Communi-Form	Pharmaceutical Consulting Group
	Comvestrix Corp.	Pharmaceutical Software Laboratories, Inc.
	Comet	Pharmetrics
	Computer Sciences Corporation (*)	Phoenix Marketing Group, Inc.
	Data Analysis Systems, Inc.	Powell and Associates
	Decision Resources, Inc.	Prescription Card Services, Inc. (PCS)
	Della Marketing Concepts	Print Data Corporation
	Dendrite	Professional Detailing Inc.
	Diversified Pharmaceutical Services, Inc.	ProMetrics Consulting, Inc.
	EDS	Photocare Sciences
	Epsilon	Putnam & Associates
	First Image	Quintiles Transnational
	Forms Distribution Center	Rx Analyst
	Futurion Forecasting Associates, Inc.	SCC
	Hann & DePalmer	Scott-Levin Associates, Inc.
	HCIA, Inc.	Siebel Systems
	Health Products Research, Inc.	Synygy Inc.
	Health Research Associates	Skila, Inc.
	Horizon Systems, Inc.	SMG Marketing Group, Inc.
	Infinite Data Structures, Inc. (IDS)	Software Associates International
	Information Builders	Source Informatics, Inc.
	Information Resources, Inc. (IRI)	Strategic Information Associates
	Ingenix	Strategic Mapping, Inc. (Claritas)
	ISIS	Strategic Marketing Corp. (SMC)
	Interdata S.A	Strategic Marketing Group (SMG)
	Integrated Systems Solutions Corp. (ISSC)	Strategic Network Designs, Inc.
	Intersearch/Sofres	Tactician Corporation
	Karl Analytical	Taylor-Nelson/AGB
	Kelly/Waldron & Co.	Technovations, Inc.
	KWS & P, Inc.	The Alexander Group
	Ketron	The Vandeveer Group
	Laser Print and Image, Inc.	Total Research
	Market Measures	Windsoft, Inc.
	McKinsey & Company (*)	Ziment
	Medi-Promotions, Inc.	ZS Associates

	

 

Note: For the companies identified
above with an (“*”), the restriction applies with respect to the divisions and
groups within those companies which provide information, technology or consulting
services to organizations in the pharmaceutical and health care industries.  

	

27 

	

 

EXHIBIT 5 

	 	RESTRICTION
For the term of this Agreement, IMS will not grant a license to the same or substantially
the same Xponent® Profiler Data being licensed by Licensee hereunder, which includes
the products, therapeutic classes and total volume being purchased by Licensee, for uses
A, C and D defined on Exhibit 3 and for use in sample fulfillment programs that are in
direct competition with Single Source Sampling (as that program is defined as of August
1, 2000), to the following companies: 

	 	 	 

	 	                             o  	Epsilon 

	 	 	 

	 	o  	NDC
Health Information Services  

	 	 	 

	 	                             o  	PPS
Medical Marketing Services, Inc. 

	 	 	 

	 	o  	Medical
Marketing Service Inc. 

	 	 	 

	 	o  	Phoenix
Marketing Group

	 	
Notwithstanding
the above, IMS shall be allowed to grant such a license if it can be demonstrated that IMS
or any of its predecessors had previously done so prior to August 1, 2000. 

	 	
Notwithstanding
the above, IMS shall not be precluded or limited or restricted in any way from entering
into a Third Party Access Agreement whereby a company or companies listed above is the
third party or parties entitling it to use the Data for uses A, C and D as noted on
Exhibit 3. For purposes of the paragraph, “Third Party Access Agreement” shall
mean an agreement entered into with IMS, IMS’s client and a third party contractor or
agent of IMS’s client, whereby the third party is permitted access to IMS data. 

	 	
Notwithstanding
the above, the limitation upon IMS’s ability to grant a license to Xponent Profiler
Data to a particular company listed above shall not apply in the event that (a) such
company becomes an affiliate of IMS, (b) IMS or its affiliates acquires an ownership
interest or makes an investment in such company or its affiliates, whether in the form of
equity, debt or otherwise (but excluding ownership of less than one percent (1%) of the
issued and outstanding shares of capital stock of any company listed on additional
securities exchange or quoted by the National Association of Securities Dealers Automated
Quotation System), or (c) IMS or its affiliates enters into a partnership or joint venture
with such Company or its affiliates. As used in the preceding sentence, an
“affiliate” shall refer to any Person, which now or in the future controls, is
controlled by or is under common control with IMS.

IMS’s
ability to license a subset of the Xponent Profiler Data shall not be in anyway
restricted. 

	

28 

	

ADDENDUM and
AMENDMENT TO

Restated Xponent
Data License Agreement
  Dated April 26, 200
Between IMS Health Incorporated ("IMS")

                                                        and

                           Interactive Marketing Division of Synavant, Inc. ("Licensee")

	 	
 

	 	
This
Addendum and Amendment (“Addendum”) is effective as of September 1, 2002 and
supplements, modifies, and is hereby made part of the Restated Xponent Data License
Agreement dated April 26, 2001, with an effective date of September 1, 2000, between IMS
Health Incorporated and Synavant (the “Agreement”). 

	 	       
 

	1.	       
              The
following additional deliverables and associated fees will be deemed included in the Schedule of
Fees & Services of the Agreement: 

		
	            Deliverable	          Total Additional Fees

          September 2002 - August 2003
	

	 	

Selected Services                              
                              
                              $750,000

      Xponent(R)Profiler(TM)

      Up to three (3)Consulting Promotional Evaluations

      (see attached example)

Early View(TM)          
          
          
          
          See Early View Rider, Paragraph 5, Fees
for pricing schedule

Total additional Fees:          
          
          
          
          
          
          
         $750,000

          
          
          
          
          
          
          
          
          
          
     Plus Early View Fees,

          
          
          
          
          
          
          
          
          
     
as determined at time of purchase

	 	
 

	 	
 

	 	
The above deliverables are hereby included in
 the Data, Software and Services under the
Agreement, as further described in the attached Schedule of Services.

	 	       
 

	2. 	       
              Exhibit
5, entitled “Restriction”, is deemed deleted in its entirety.           In the
second sentence of Paragraph 2, the phrase “subject to Exhibit           5,” is
deleted.  

	 	
 

	 	Except
as modified above, all other terms and conditions remain the same and in effect. 

				
	               IMS Health Incorporated:	Synavant Inc.	 	 
	
               By:  TOM STAZZONE	
By:  KERRY COLLINS		
	
               Name:  Tom Stazzone 	
Name:  Kerry Collins		
	
               
Title:  Corp. Director	
Title:  V. P. Operations		
	
               
Date:  4/15/2003	
Date:  4/1/2003amendmet to restated xponent data license agreement

	

Amendment To
Restated Xponent Data
License Agreement
Dated April 26, 2001
Between IMS Health Incorporated And

Interactive Marketing Division of Synavant, Inc. 

This amendment
(“Amendment”), effective as of June 16, 2003 (the “Effective Date”),
is entered into by and among IMS Health Incorporated (“IMS”), Synavant, Inc.
(“Licensee”), and Dendrite International, Inc. (“Dendrite”) and
supplements, modifies and is hereby made part of the Restated Xponent Data License
Agreement dated April 26, 2001, with an effective date of September 1, 2000, as amended by
an Addendum and Amendment to such agreement dated September 1, 2002, (the
“Agreement”) between IMS and Licensee. 

1. Background 

Licensee has agreed to be acquired by
Dendrite and/or certain of its affiliates (such acquisition hereinafter referred to as the
“Transaction”). In connection with the Transaction, the parties, by a letter
agreement dated May 8, 2003 (the “Extension Agreement”) agreed to enter into an
extension of the Agreement on the terms stated in this Amendment. 

2. Term Extension 

The term of the Agreement is hereby
extended to August 31, 2005. 

3. Fees 

Commencing as of the Effective Date,
the annual fees payable by Licensee to IMS for the services provided under the Agreement
are hereby restated to one million five hundred thousand dollars ($1,500,000). IMS shall
invoice one quarter of the annual fee on a quarterly basis in advance (i.e., IMS shall
invoice three hundred and seventy-five thousand dollars ($375,000) on or about September
1st, December 1st, March 1st, and June 1st of
each Contract Year commencing on September 1, 2003) and on or about September
1st, 2003 shall invoice any difference between the pro-rata portion of such
annual fee applicable to the period from the Effective Date to September 1, 2003 and the
fee due under the Agreement (prior to the modification to such fee under this Amendment)
applicable to such period which was previously billed to Licensee. 

4. Termination Rights 

In addition to the other termination
rights under the Agreement, Dendrite and/or Licensee may terminate the Agreement upon
thirty (30) days advance written notice to IMS in the event that IMS terminates, pursuant
to section 4.c of the Extension Agreement, the Cross License Agreement, dated as of August
31, 2000, as extended, between IMS and Licensee (the “Pharbase Cross License”),
such termination of the Agreement to be effective as of the effective termination date of
the Pharbase Cross License, unless agreed otherwise by the parties. In the event of such
termination, IMS shall provide to Licensee an appropriate credit or refund, as applicable,
of the un-earned portion of the fees under the Agreement in a pro-rata amount applicable
to the period following the effective termination of the Agreement. 

	

Except as herein modified and
supplemented, all other terms and conditions of the Agreement remain in full force and
effect. 

				
	IMS Health Incorporated

	Synavant, Inc.

	 	 
	

By:  ROBERT H. STEINFELD	

By:  CHRISTINE PELLIZZARI		
	
Name:  Robert H. Steinfeld	
Name:  Christine Pellizzari
	
Title:  SVP - General Counsel	
Title:  Secretary		
	
Date:  June 16, 2003	
Date:  June 16, 2003	

				
	Dendrite International, Inc.

	

	 	 
	

By:  CHRISTINE PELLIZZARI	

		
	
Name:  Christine Pellizzari	

	
Title:  Vice President, General Counsel and
            Secretary	
		
	
Date:  June 16, 2003	
	

-2-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00055-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00055-of-00352.parquet"}]]